Tango Therapeutics Names CFO, Operations and Strategy Heads to Advance Vopimetostat
Tango Therapeutics added Matthew Gall as CFO and appointed Yen-Ching Chua and Janice Kapty, PhD to senior roles overseeing late-stage development and strategy for PRMT5 inhibitor vopimetostat targeting pancreatic cancer approval. Gall led finance at Kalaris and iTeos; Chua oversaw trials at Novartis; Kapty managed strategy at BMS.
1. Leadership Appointments
Tango Therapeutics has appointed Matthew Gall as Chief Financial Officer effective April 15, Yen-Ching Chua as Chief Development Operations Officer effective June 1, and Janice Kapty, PhD as Senior Vice President, Corporate Strategy and Project Leadership effective April 15. These changes aim to bolster late-stage development functions.
2. Executive Backgrounds
Gall brings extensive finance, corporate development and capital-raising experience from roles at Kalaris Therapeutics and iTeos Therapeutics. Chua has led global clinical operations and compliance at Novartis and Debiopharm, while Kapty directed project strategy and management at Bristol Myers Squibb and Arvinas.
3. Strategic Impact
The new leadership is tasked with accelerating vopimetostat, a selective PRMT5 inhibitor under investigation for pancreatic cancer, through late-stage trials and toward regulatory submission. Tango expects key clinical data for vopimetostat, including combination results with RAS(ON) inhibitors, later this year.